Clinical info: Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV

In this update, several sections of the guidelines have been revised with discussions on factors that clinicians should consider when selecting an antiretroviral (ARV) regimen for individuals who acquire HIV after having received long-acting cabotegravir (CAB-LA) for HIV pre-exposure prophylaxis (PrEP). Because of the long half-life of CAB-LA, the Panel on Antiretroviral Guidelines for Adults and Adolescents (the Panel) recommends performing genotypic resistance testing, including testing for integrase resistance, before starting antiretroviral therapy (ART). If resistance testing results are not available before ART initiation, the Panel recommends initiating a boosted darunavir regimen while awaiting results confirming no resistance to the integrase strand transfer inhibitor (INSTI) drug class. The sections updated with this new information include the following:

• Laboratory Testing for Initial Assessment and Monitoring of Patients with HIV Receiving Antiretroviral Therapy
• Drug-Resistance Testing
• What to Start
• Early (Acute and Recent) HIV Infection

Additional details to the following link: https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/whats-new-guidelines